Fragment based discovery of a novel and selective PI3 kinase inhibitor.
Hughes, S.J., Millan, D.S., Kilty, I.C., Lewthwaite, R.A., Mathias, J.P., O'Reilly, M.A., Pannifer, A., Phelan, A., Stuhmeier, F., Baldock, D.A., Brown, D.G.(2011) Bioorg Med Chem Lett 21: 6586-6590
- PubMed: 21925880 
- DOI: https://doi.org/10.1016/j.bmcl.2011.07.117
- Primary Citation of Related Structures:  
3ZVV, 3ZW3 - PubMed Abstract: 
We report the use of fragment screening and fragment based drug design to develop a PI3γ kinase fragment hit into a lead. Initial fragment hits were discovered by high concentration biochemical screening, followed by a round of virtual screening to identify additional ligand efficient fragments. These were developed into potent and ligand efficient lead compounds using structure guided fragment growing and merging strategies. This led to a potent, selective, and cell permeable PI3γ kinase inhibitor with good metabolic stability that was useful as a preclinical tool compound.
Organizational Affiliation: 
Worldwide Medicinal Chemistry, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK. samantha.hughes@pfizer.com